Back to top
more

BellRing Brands (BRBR)

(Delayed Data from NYSE)

$49.67 USD

49.67
1,540,553

-1.56 (-3.05%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System

by Zacks Equity Research

Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.

Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage

by Zacks Equity Research

Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.

Bruker (BRKR) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.

Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

by Zacks Equity Research

Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.

Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.

ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization

by Zacks Equity Research

ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.

Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System

by Zacks Equity Research

The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.

Should Value Investors Buy BellRing Brands (BRBR) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Hill-Rom (HRC) PSS Growth Solid Despite Tough Y/Y Comparison

by Zacks Equity Research

Hill-Rom's (HRC) recent launches, including the Helion Integrated Surgical System in the United States, buoy optimism.

Abbott (ABT) Receives FDA Nod for Amplatzer Amulet Device

by Zacks Equity Research

The FDA's go-ahead for Abbott's (ABT) Amulet will offer a unique treatment option in the United States that seals off the left atrial appendage entirely without any blood-thinning drugs.

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).

Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic

by Zacks Equity Research

Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.

Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales

by Zacks Equity Research

Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Strong fiscal fourth-quarter performance in the Food Safety and Animal Safety segments drove the top line for Neogen (NEOG).

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.

Medtronic (MDT) to Expand Neuroscience Line With XENT Buyout

by Zacks Equity Research

Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.

New Strong Buy Stocks for August 10th

by Zacks Equity Research

ACI, BRBR, CRI, DLA, and WCC have been added to the Zacks Rank #1 (Strong Buy) List on August 10, 2021.

BellRing Brands (BRBR) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 36.36% and 15.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Receives FDA Approval for OCT Imaging Platform

by Zacks Equity Research

The FDA authorization for Abbott's (ABT) OCT imaging platform powered by the Ultreon Software is expected to broaden its accessibility to physicians.

Is BellRing Brands (BRBR) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) Introduces New Drug Coated Balloon Catheter

by Zacks Equity Research

Medtronic's (MDT) newly-launched Prevail DCB demonstrates impressive safety and drug deliverability, utilizing a rapid absorption drug to treat patients with coronary artery disease.

Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition

by Zacks Equity Research

Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.